Bayer wins Japan nod for finerenone in broad heart failure population
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Subscribe To Our Newsletter & Stay Updated